International Journal of Engineering Research and Science & Technology

IJERST

ISSN : 2319-5991

www.ijerst.com

Email: editor@ijerst.com or editor.ijerst@gmail.com

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

SELF-SUPERVISED GRAPH NEURAL NETWORKS FOR PREDICTING SIDE EFFECTS FROM DRUG-DRUG INTERACTIONS

[1] *Shaik Zuber, MCA Student, Department of MCA*
[2] *Bushra Tahseen, MCA, (Ph.D), Associate Professor, Department of MCA*
[12]*Dr KV Subba Reddy Institute of Technology, Dupadu, Kurnool*

ABSTRACT

Because of their effects on mortality, morbidity, and healthcare expenses, adverse drug reactions (ADRs) brought on by drug-drug interactions are a global public health concern that requires study. The ever-increasing complexity of treatments and the ageing of the population in many areas have presented significant hurdles for the healthcare industry. There is currently no established technique for identifying these negative drug interactions until patients report them after the medication is put on the market. Furthermore, a number of studies demonstrate how difficult it is to identify these uncommon occurrences in clinical trials conducted prior to the drug's distribution. Therefore, there is an urgent need for a trustworthy and effective method to anticipate these adverse effects prior to the drug's entry into the market. We created an efficient framework to describe drug-drug interactions by using the spatial and physical characteristics of pharmaceuticals by expressing them as molecular graphs, utilising the power of Graph Neural Networks and the knowledge representation capabilities of self-supervised learning. We created a method that mimics the kinetics of a chemical reaction using this method. We attain state-of-the-art results by achieving a precision of 75% and an accuracy of 90% on the test dataset after training and testing our strategy on the Therapeutic Data Commons (TDC) Two SIDES Polypharmacy Dataset. In order to test our technique on the drug-drug interaction domain, we also conduct a case study on the DrugBank dataset and compare our findings on the interaction type prediction job. We get outstanding results with precision, F1, and accuracy of 99%. Our investigation and experimental methods provide a foundation for future studies on drug-drug interaction-based side-effect prediction and the use of graph neural networks in molecular biology.

I. INTRODUCTION

Because computational approaches may identify potential adverse effects before clinical trials begin, they offer considerable promise for reducing the cost and health risks associated with medication development. Numerous learning-based techniques have been put forth to forecast drug side effects based on a variety of features, including drug chemical structures [25, 1, 23, 8, 19, 34, 17, 9, 2, 5], drug-protein interactions [35, 33, 8, 19, 34, 17, 37, 2, 15, 36], protein-protein interactions (PPI) [8, 9], metabolic network activity [38, 26], pathways, phenotype data, and gene annotations [8]. Deep learning models have been used recently to predict side effects in parallel with the previously mentioned methods: (i) [31] compares the side effect prediction performance using different chemical fingerprints extracted using deep architectures, and (ii) [4] uses biological, chemical, and semantic information on drugs in addition to clinical notes and case reports.

Although these techniques have shown promise in anticipating adverse drug reactions (ADRs, sometimes known as drug side effects), the characteristics they employ are not cell or condition (i.e., dosage) specific and are only based on outside information about the drugs (i.e., drug-protein interactions, etc.). Wang et al. (2016) use the LINCS L1000 project data to solve this problem [32]. This study tracks changes in

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

gene expression in a variety of human cell lines after treatment with a wide range of medications and small-molecule substances. [32] offers the first thorough, objective, and economical prediction of ADRs based on the gene expression patterns of the treated cells. The issue is formulated as a multi-label classification assignment in the study. Their findings imply that context-dependent information for the side-effect prediction job is provided by the gene expression patterns. Although there are 473,647 tests for 20,338 compounds in the LINCS dataset, their approach only uses the best quality experiment for each medication in order to reduce noise. This indicates that the majority of the expression data is not utilised, which may indicate that the prediction performance may be improved. Additionally, by converting gene expression features into biological term enrichment vectors, their approach carries out feature engineering. In this study, we examine whether integrating gene expression and drug structure data may be more effectively used in a deep learning framework without requiring feature engineering.

In this work, we provide Deep Side, a deep learning framework for ADR prediction. The sole sources of information used by Deep Side are (i) in vitro gene expression profiling experiments (GEX) and their experimental meta data (such as cell line and dose, or META) and (ii) the substances' chemical structures (CS). The SIDER dataset serves as the ground truth for drug-ADR pair labelling, and our models are trained on the whole LINCS L1000 dataset [13]. A multi-layer perceptron (MLP), MLP with residual connections (Res MLP), multi-modal neural networks (MMNN. Concat and MMNN. Sum), multi-task neural networks (MTNN), and SMILES convolutional neural networks (SMILES Conv) are the five designs that we test.

We examine the contributions of various characteristics and provide a thorough assessment of the aforementioned designs. Our tests demonstrate that CS is a reliable indicator of adverse consequences. The state-of-the-art findings given in [32], which employs both GEX (high quality) and CS features, are improved by _11% macro-AUC and _2% micro-AUC by the basic MLP model, which uses CS features as input. The greatest results among MLP-based methods are obtained by the multi-modal neural network model, which employs CS, GEX, and META features with summing in the fusion layer (MMNN. Sum), which achieves 0:79 macroAUC and 0:877 micro-AUC. Additionally, we discover that the information gleaned from the GEX dataset is overwhelmed when the chemical structure characteristics are completely used in a complicated model such as ours. Out of all the suggested designs, the convolutional neural network that just employs the SMILES string representation of the drug structures performs the best, with a 13:0% macro-AUC and a 3:1% micro-AUC improvement over the state-of-the-art technique. Lastly, examining the confident false positive predictions reveals side effects that are documented in the literature but not in the ground truth dataset. The implementation and release of Deep Side may be found at http://github.com/OnurUner/DeepSide.

II. LITERATURE SURVEY

Adrecs is an ontology database designed to help standardise and categorise adverse drug response terminology in a hierarchical manner.

Jin, H.J., Liu, K., Ji, Z.L., Cai, M.C., Xu, Q., Pan, Y.J., Pan, W., Ji, N., Li, Y.B.

During standard medication treatment, adverse drug responses (ADRs) are unpleasant and unanticipated side effects. They are mostly to blame for the failure of new medication development and have resulted in a considerable clinical burden. The overuse of ADR terminology has therefore significantly impeded the needed molecular knowledge and in silico assessment of medication (or candidate) safety in the laboratory. A specialised ADR word system that goes beyond a basic lexicon is also necessary

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

given the increasing influence of bioinformatics and systems biology in toxicological research. The comprehensive ADR ontology database Adverse Drug Reaction categorisation System (ADReCS; http://bioinf.xmu.edu.cn/ADReCS) offers hierarchical categorisation of ADR words in addition to ADR standardisation. In order to create an ADR–ADR relationship, the ADR words were first given distinct digital IDs and then arranged neatly into a four-level ADR hierarchy tree. The database now contains 34 796 synonyms and 6544 standard ADR words. It also includes data on 134 022 drug-ADR pairings and 1355 medications with a single active component. In conclusion, ADReCS gives users the chance to directly calculate ADR words and offers hints for identifying common characteristics that underlie ADRs.

Using an interpretable deep learning system to forecast adverse medication interactions

Dey, S., Zhang, P., Hu, J., Fokoue, A., and Luo, H.:

Context Unintentional and dangerous side effects brought on by regular medication usage are known as adverse drug reactions, or ADRs. Drug safety may be improved and costs can be decreased by anticipating and avoiding adverse drug reactions (ADRs) early in the drug development process. Techniques In order to simultaneously forecast ADRs and identify the chemical substructures linked to those ADRs without specifying the substructures beforehand, we constructed machine learning models in this article, including a deep learning framework. Findings When we compared our model's performance to 10 other cutting-edge fingerprint models, we discovered that the deep learning model's neural fingerprints performed better than any other technique in terms of predicting ADRs. We determined significant molecular substructures linked to certain ADRs using feature analysis of drug structures, and we evaluated these correlations statistically. Conclusions A promising method for locating dangerous elements inside molecular structures is the deep learning model with feature analysis, substructure identification, and statistical evaluation. It may also aid in enhancing the assessment of medication safety.

Adult anaemia caused by chemotherapy: prevalence and management

Itri, L.M. and Groopman, J.E.:

A typical side effect of myelosuppressive chemotherapy is anaemia, which lowers a cancer patient's functional ability and quality of life (QOL). Red blood cell transfusions are used to treat severe anaemia, although conservative management of mild-to-moderate anaemia in chemotherapy patients has long been practiced since it was thought to be clinically inconsequential. The significant disregard for thorough and standardised reporting of all levels of chemotherapy-induced anaemia is a reflection of this practice. In order to characterise and document the incidence and severity of chemotherapy-induced anaemia, we conducted a thorough review of published chemotherapy trials of the most popular single agents and combination chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults. The findings support a comparatively high frequency of mild-to-moderate anaemia, despite noted shortcomings in the classification and reporting of treatment-related anaemia. These closely associated issues are becoming better understood thanks to recent developments in evaluating the links between anaemia, tiredness, and quality of life in cancer patients. There is growing clinical evidence that mild-to-moderate anaemia brought on by chemotherapy causes a noticeable decline in a patient's energy level and quality of life. On the basis of results and haemoglobin levels, future studies might provide new categories of chemotherapy-induced anaemia that could direct treatment measures. Patients' and oncologists' perceptions that milder forms of anaemia must be tolerated untreated may change as more focus is placed on the quality of life (QOL) of cancer

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

patients and as research sheds more light on the connections between haemoglobin levels, patient health, and symptoms.

Using deep residual learning to recognise images

He, K., Sun, J., Zhang, X., and Ren, S.:

Training deeper neural networks is more challenging. In order to facilitate the training of networks that are far deeper than those previously used, we provide a residual learning approach. Rather than learning unreferenced functions, we explicitly reformulate the layers as learning residual functions with reference to the layer inputs. We provide thorough empirical proof that these residual networks are simpler to optimise and that a significant increase in depth may improve accuracy. We test residual nets with a depth of up to 152 layers on the ImageNet dataset, which is 8× deeper than VGG nets [40] but still less complicated. On the ImageNet test set, an ensemble of these residual nets achieves an error of 3.57%. On the ILSVRC 2015 classification task, this result took first place. Analysis of CIFAR-10 with 100 and 1000 layers is also presented. For many visual identification tasks, the depth of representations is crucial. We achieve a 28% relative improvement on the COCO object identification dataset, just because of our very deep representations. Our contributions to the ILSVRC & COCO 2015 competitions1 were built on deep residual nets, and we took first place in the ImageNet detection, ImageNet localisation, COCO detection, and COCO segmentation tasks.

Predicting negative drug side effects

Chen, J.Y., Huang, L.C., and Wu, X.:

Determining the prevalence of adverse effects in people is a major concern in pharmacological risk-benefit analysis. Currently, randomised controlled clinical studies are used to experimentally determine frequencies. We provide a machine learning system that may be used to forecast pharmacological side effect frequencies computationally. Our matrix decomposition approach learns reliable and scientifically interpretable latent signatures of medications and adverse effects. We demonstrate the effectiveness of our method on 994 adverse effects from every human physiological system and 759 structurally and therapeutically varied medications. Our method may be used to forecast the frequencies of additional, as-yet-unidentified, adverse effects for any medication for which a limited set of side effect frequencies have been determined. We demonstrate that the biology underpinning medication action may be inferred from our model: The unique anatomical classifications of the medications and their particular routes of administration are connected to the individual elements of the drug signatures..

III. SYSTEM ANALYSIS AND DESIGN

EXISTING SYSTEM

Every scientific field exhibits the presence of artificial intelligence (AI). Nevertheless, one of the most studied fields is artificial intelligence in chemistry. Reference [14] effectively modelled an FDA/OTR MultiCASE model that predicts the carcinogenicity of medicines and QSAR, which predicts the carcinogenic potency of aromatic amines. It's also important to note that [15] used 2D similarity fingerprints because of their effectiveness and ease of use in calculating drug-drug interactions to avoid negative side effects. The development of neural networks (NN) and machine learning (ML) has increased interest in drug discovery. Reference [16] demonstrates that in-silico-based multi-drug models may be constructed to impute missing IC50 values using non-parametric machine learning techniques by using genomic markers from the cell lines and chemical information from medications. Using four features—drug phenotypic, therapeutic, chemical, and genetic properties—Reference [17] computes the similarity of drug pairs using predictive models such as Naive Bayes, Decision Tree, k-nearest neighbour, logistic regression, and support vector machine (SVM). While [19] employs Discriminative Vector Machines for precise protein-protein interaction prediction, reference [18] describes a two-stage hybrid

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

approach model that first uses a feature-based binary classifier to identify positive instances, followed by a Long Short Term Memory (LSTM) based classifier to classify positive instances.

It is commonly recognised that the Graph Neural Network (GNN) Model [20] method works well in chemical graphs, including but not limited to drug development, protein-protein interaction networks, and molecular structure analysis. Applications and activities like [21] and [22] have made use of Graph Attention Networks (GAT) [10]. The Graph Convolution technique, which is used in Reference [23], enables nodes to compile data from their closest neighbours in the graph. Additionally, [25] addressed the formulation of spectral graph convolution networks for directed graphs, and [24] uses spectral graph convolutions that use the eigenvalues and eigenvectors of the graph Laplacian matrix to define convolutional operations, allowing information to propagate through the graph. Utilised in [26] and [27], GraphSAGE [11] has shown a significant improvement in performance in transductive-based prediction tasks for intricate and large graph networks.

Disadvantages

• Data complexity: To detect side effects or adverse drug reactions, the majority of machine learning models now in use need to be able to correctly comprehend large and intricate datasets.

• Data availability: In order to provide precise predictions, the majority of machine learning models need a lot of data. The accuracy of the model may degrade if data is not accessible in large enough amounts.

• Inaccurate labelling: The accuracy of the machine learning models that are now in use depends on how well the input dataset was used for training. Inaccurate labelling of the data prevents the model from producing reliable predictions.

PROPOSED SYSTEM

The goal of the research is to lower the quantity of clinical hospitalisations brought on by adverse drug reactions. Based on the drug's chemical makeup and the kinetics of their interactions, our suggested framework forecasts the adverse consequences of drug-drug interactions. This guarantees that factors like the calibre of the healthcare, the subjectivity of the reports, and the calibre of the doctor are removed and permits a comprehensive and early assessment of side effects brought on by such unfavourable responses. Rather, a probabilistic and scientific perspective is offered to forecast adverse outcomes. Our work is one of the first to use deep learning to investigate the mathematical relationships that underlie side effect prediction and drug-drug interactions.

By portraying the medications involved in the reaction as molecules, we provide a new method for predicting adverse effects resulting from drug-drug interactions using Graph Neural Networks. Atoms serve as the graph's nodes, while chemical bonds serve as its edges. This allows molecules' spatial and physical characteristics to be used via their visual depiction. Graph neural networks are not used to represent the physical and bonding characteristics of chemical compounds, nor are the structures of the molecules involved in the drug-drug interaction used in the approaches that have been developed so far to predict side effects.

We create a Dual Input Graph Neural Network Hybrid Model with a two-stage training phase in order to capture the kinetics of a chemical reaction and efficiently use the spatial and physical characteristics of both reactants. By sharing characteristics across the two reactants, the Dual Input framework is intended to simulate the dynamics of a chemical reaction. Despite the system's complexity, we are able to create a steady model training curve. To guarantee that a knowledge base obtained from the characteristics of the interacting medications is passed to the side effect prediction job, each reactant is further pre-trained. Even though this framework is still in its early phases of development, it produces

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

precision and accuracy outcomes that are at the forefront of the field.

The Two Sides poly-pharmacy side effects dataset from Therapeutic Data Commons (TDC) served as the basis for our investigation. Our studies serve as a baseline standard since this is one of the few datasets for side-effect prediction using drug-drug interactions. Thus, we hope that our research will serve as a foundation for side effect prediction and pave the way for further investigations into the domains of drug-drug interactions and molecular graph neural networks.

We provide an experimental validation of our suggested framework on the DrugBank Dataset as the TwoSides poly-pharmacy side effects dataset is the only one available for side effects prediction and there aren't any prior benchmarks on the same. Although predicting the kind of drug-drug interaction is the last objective for the DrugBank dataset, we are able to attain state-of-the-art results for our proposed framework on this task as well by comparing our findings with relevant research. We demonstrate that our suggested framework can accurately simulate drug-drug interactions and, even with a modified prediction job, can simulate the dynamics of a chemical interaction. It also establishes the groundwork for future studies in the field of drug-drug interactions and bioinformatics.

ADVANTAGES

By modelling the characteristics of drug molecules and using the pattern recognition capabilities of self-supervised learning and the possibilities of ensemble learning, we provide a unique framework for modelling drug-drug interactions using Graph Neural Networks. We may use the sophisticated representations and operations provided by Graph Neural Networks to simulate the atomic and bond-level features of chemical compounds as they can be represented as molecular graphs.

Because of recent advancements like Graph Convolution Network, Graph Attention Network, and SAGE, as well as their exceptional performance on graph-level tasks, Graph Neural Networks have become more and more popular, making them a dependable choice in a variety of industries. Even though Graph Neural Networks have certain drawbacks, like under-fitting and the requirement to produce high-quality vertex embeddings, fine-tuning pre-trained weights and ensemble approaches significantly improve Deep Learning models' performance, opening the door for more research into Graph Neural Networks and their uses in drug research.

SYSTEM ARCHIECTURE



IV. IMPLEMENTATION

Modules

Service Provider

The Service Provider must use a working user name and password to log in to this module. He may do many tasks after successfully logging in, including Train & Test Data Sets, See the Accuracy of Trained and Tested Datasets in a Bar Chart View Accuracy Results for Trained and Tested Datasets, Download Predicted Data Sets, View Cyber Attack Prediction Status Ratio, and View Cyber Attack Prediction Status See the results of the Cyber Attack Prediction Status Ratio. See Every Remote User.

View and Authorize Users

The administrator may see a list of all registered users in this module. Here, the administrator may see the user's information, like name, email, and address, and they can also grant the user permissions.

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

Remote User

A total of n users are present in this module. Before beginning any actions, the user needs register. Following registration, the user's information will be entered into the database. Following a successful registration, he must use his password and authorised user name to log in. Following a successful login, the user may do tasks including registering and logging in, predicting the status of cyberattacks, and seeing their profile.

ALGORITHMS

DECISION TREE CLASSIFIERS

Decision tree classifiers are effectively used in a wide range of fields. Their capacity to extract descriptive decision-making information from the provided data is their most crucial characteristic. Training sets may be used to create decision trees. The following is the process for this kind of creation based on the set of objects (S), each of which belongs to one of the classes C1, C2, …, Ck:

Step 1: The decision tree for S has a leaf labelled with the class if every item in S is a member of the same class, such as Ci.

Step 2. If not, let T be a test with the potential results O1, O2,..., On. The test divides S into subsets S1, S2,… Sn, where each item in Si has result Oi for T, because each object in S has a single outcome for T. T serves as the decision tree's root, and we construct a subsidiary decision tree for each outcome Oi by recursively applying the same process to the set Si.

Gradient boosting

One machine learning method for classification and regression problems is gradient boosting. Usually decision trees, it provides a prediction model in the form of an ensemble of weak prediction models.[1] [2] The resultant technique, known as gradient-boosted trees, often performs better than random forest when a decision tree is the weak learner.Like other boosting techniques, a gradient-boosted trees model is constructed step-by-step; however, it goes one step further by allowing optimisation of an arbitrary differentiable loss function.

K-Nearest Neighbors (KNN)

- A simple but very effective classification technique that uses a similarity metric
- Non-parametric learning and lazy learning don't "learn" until the test example is provided.
- We use the training data to determine the K-nearest neighbours of any fresh data that has to be classified.

Example

- The training dataset comprises the k-closest examples in feature space, which is defined as a space containing categorisation variables (non-metric variables).
- Learning is based on instances, which also facilitates lazy learning because it may take some time for an instance near the input vector for testing or prediction to occur in the training dataset.

Logistic regression Classifiers

The relationship between a collection of independent (explanatory) factors and a categorical dependent variable is examined using logistic regression analysis. When the dependent variable simply has two values, like 0 and 1 or Yes and No, the term logistic regression is used. When the dependent variable contains three or more distinct values, such as married, single, divorced, or widowed, the technique is sometimes referred to as multinomial logistic regression. While the dependent variable's data type differs from multiple regression's, the procedure's practical application is comparable.

When it comes to categorical-response variable analysis, logistic regression and discriminant analysis are competitors. Compared to

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

discriminant analysis, many statisticians believe that logistic regression is more flexible and appropriate for modelling the majority of scenarios. This is due to the fact that, unlike discriminant analysis, logistic regression does not presume that the independent variables are regularly distributed.

Both binary and multinomial logistic regression are calculated by this software for both category and numerical independent variables. Along with the regression equation, it provides information on likelihood, deviance, odds ratios, confidence limits, and quality of fit. It does a thorough residual analysis that includes diagnostic residual plots and reports. In order to find the optimal regression model with the fewest independent variables, it might conduct an independent variable subset selection search. It offers ROC curves and confidence intervals on expected values to assist in identifying the optimal classification cutoff point. By automatically identifying rows that are not utilised throughout the study, it enables you to confirm your findings.

V. SCREEN SHOTS



VI. CONCLUSION

The process of developing pharmaceutical drugs is a drawn-out and difficult one. Unexpected adverse drug reactions (ADRs) during the drug development process have the potential to halt or restart the whole process. As a result, it is crucial to foresee the drug's adverse effects in advance during the design stage. To account for factors like dosage, time interval, and cell line, we forecast ADRs using our Deep Side framework, which combines chemical structure with context-related (gene expression) information. The suggested MMNN model outperforms models

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

that just employ chemical structure (CS) fingerprints in terms of accuracy by using GEX and CS as integrated features. Considering that we are simply attempting to predict the condition-independent side effects, the stated accuracy is significant. Lastly, by using convolution on the SMILES representation of drug chemical structure, the SMILES Conv model performs better than any other method.

REFERENCES

1. Atias, N., Sharan, R.: An algorithmic framework for predicting side e_ects of drugs. Journal of Computational Biology 18(3), 207{218 (2011)
2. Bresso, E., Grisoni, R., Marchetti, G., Karaboga, A.S., Souchet, M., Devignes, M.D., Sma • _l-Tabbone, M.: Integrative relational machine-learning for understanding drug side-e_ect pro_les. BMC bioinformatics 14(1), 207 (2013)
3. Cai, M.C., Xu, Q., Pan, Y.J., Pan, W., Ji, N., Li, Y.B., Jin, H.J., Liu, K., Ji, Z.L.: Adrecs: an ontology database for aiding standardization and hierarchical classi_cation of adverse drug reaction terms. Nucleic acids research43(D1), D907{D913 (2014)
4. Dey, S., Luo, H., Fokoue, A., Hu, J., Zhang, P.: Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics 19 (12 2018). https://doi.org/10.1186/s12859-018-2544-0
5. Dimitri, G.M., Li_o, P.: Drugclust: A machine learning approach for drugs side effects prediction. Computational Biology and Chemistry 68, 204 { 210 (2017). https://doi.org/https://doi.org/10.1016/j.compbiolchem.2017.03.008
6. Groopman, J.E., Itri, L.M.: Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 91(19), 1616{1634 (1999)
7. He, K., Zhang, X., Ren, S., Sun, J.: Deep residual learning for image recognition. In: The IEEE Conference on Computer Vision and Pattern Recognition (CVPR) (June 2016)
8. Huang, L.C., Wu, X., Chen, J.Y.: Predicting adverse side e_ects of drugs. BMC genomics 12(5), S11 (2011)
9. Huang, L.C., Wu, X., Chen, J.Y.: Predicting adverse drug reaction pro_les by integrating protein interactionnetworks with drug structures. Proteomics 13(2), 313{324 (2013)
10. Io_e, S., Szegedy, C.: Batch normalization: Accelerating deep network training by reducing internal covariate shift. arXiv preprint arXiv:1502.03167 (2015)
11. Kim, S., Thiessen, P.A., Bolton, E.E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B.A.,et al.: Pubchem substance and compound databases. Nucleic acids research 44(D1), D1202{D1213 (2015)
12. Krizhevsky, A., Sutskever, I., Hinton, G.E.: Imagenet classi_cation with deep convolutional neural networks. In: Advances in neural information processing systems. pp. 1097{1105 (2012)
13. Kuhn, M., Letunic, I., Jensen, L.J., Bork, P.: The sider database of drugs and side e_ects. Nucleic acids research 44(D1), D1075{D1079 (2015)
14. Landrum, G., et al.: Rdkit: Open-source cheminformatics (2006)
15. Lee, W., Huang, J., Chang, H., Lee, K., Lai, C.: Predicting drug side e_ects using data analytics and the integration of multiple data sources. IEEE Access 5, 20449{20462 (2017). https://doi.org/10.1109/ACCESS.2017.2755045
16. Li, Y., Yuan, Y.: Convergence analysis of two-layer neural networks with relu

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp398-407 Vol. 21, Issue 2, 2025

activation. In: Advances in Neural Information Processing Systems. pp. 597{607 (2017)
17. Liu, M., Wu, Y., Chen, Y., Sun, J., Zhao, Z., Chen, X.w., Matheny, M.E., Xu, H.: Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. Journal of the American Medical Informatics Association 19(e1), e28{e35 (2012)
18. Lopes, C.E., Langoski, G., Klein, T., Ferrari, P.C., Farago, P.V.: A simple hplc method for the determination of halcinonide in lipid nanoparticles: development, validation, encapsulation e_ciency, and in vitro drug permeation. Brazilian Journal of Pharmaceutical Sciences 53(2) (2017)
19. Mizutani, S., Pauwels, E., Stoven, V., Goto, S., Yamanishi, Y.: Relating drug{protein interaction network with drug side e_ects. Bioinformatics 28(18), i522{i528 (2012)
20. O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R.: Open babel: An open chemical toolbox. Journal of cheminformatics 3(1), 33 (2011)
21. Okubo, S., Nakatani, K., Nishiya, K.: Gastrointestinal symptoms associated with enteric-coated sulfasalazine (azul_dine en tablets). Modern rheumatology 12(3), 0226{0229 (2002)
22. Pal, S.K., Mitra, S.: Multilayer perceptron, fuzzy sets, and classi_cation. IEEE Transactions on Neural Networks 3(5), 683{697 (Sep 1992). https://doi.org/10.1109/72.159058
23. Pauwels, E., Stoven, V., Yamanishi, Y.: Predicting drug side-e_ect pro_les: a chemical fragment-based approach. BMC bioinformatics 12(1), 169 (2011)
24. Polatti, F., Viazzo, F., Colleoni, R., Nappi, R.E.: Uterine myoma in postmenopause: a comparison between two therapeutic schedules of hrt. Maturitas 37(1), 27{32 (2000)
25. Scheiber, J., Jenkins, J.L., Sukuru, S.C.K., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S.,Hamon, J., Urban, L., et al.: Mapping adverse drug reactions in chemical space. Journal of medicinal chemistry 52(9), 3103{3107 (2009)